SOHM Introduces Second Innovative Skincare Line Product, Salic-2(R) Gel for Acne

SOHM Introduces Second Innovative Skincare Line Product, Salic-2(R) Gel for Acne 
New Acne Treatment Comes on the Heels of Recent and Successful Launch
of Flagship Skincare Product, FOHM by SOHM 
BUENA PARK, CA -- (Marketwired) -- 11/07/13 --  SOHM, Inc.
(PINKSHEETS: SHMN), a generic pharmaceutical, nutraceutical and
cosmeceutical manufacturing company, today announces the launch of
its innovative Salic-2(R) Gel for acne treatment. This product is
also being manufactured as private label by SOHM for Ranbaxy
Laboratories Ltd., one of the world's leading pharmaceutical
companies and part of Daiichi Sankyo Pharmaceuticals in Japan. 
Shailesh Shah, president and CEO of SOHM, stated, "Salic-2(R) Gel is
one of the most innovative products developed by SOHM's dermatology
division for the treatment of acne. The product not only ensures that
normal acidic mantle is kept consistent but also protects the tender
skin from bacteria. We are excited to launch this product following
our successful first quarter launch of our salicylic acid face wash,
fohm by sohm at the 2013 Oscars after party, held in Hollywood."  
Sohm views the facial care product segment as an important segment in
the world's skin care industry, which is forecasted to grow by more
than 21 percent from 2010-2015 to generate almost $95 billion and
reach a volume in excess of 13 billion units. Facial care represents
the leading market segment, with more than 64 percent of overall
value.  
The company anticipates that Salic-2(R) Gel will be a competitive
player in the growing skin care industry.  
"SOHM team is confident that Salic-2(R) Gel is going to be a tough
industry competitor to similar product categories available in the
U.S. market," stated Shah. "The introduction of this second skin care
line is consistent with our goal of capturing a significant share of
the huge U.S. market through our innovative and expanding
cosmeceutical product pipeline." 
ABOUT SOHM, Inc. 
SOHM, Inc. is a generic pharmaceutical manufacturer that produces and
markets generic drugs covering all major treatment categories.
Besides generic drugs, SOHM also has manufacturing facilities for
food supplements and cosmetics. The Company has global headquarters
located in California, U.S., with manufacturing facilities in India.
SOHM exports generic pharmaceuticals worldwide, placing a heavy focus
on distribution in emerging markets in Africa, Latin America, and
Southeast Asia. For more information visit the company's website at:
www.sohm.com  
SAFE HARBOR STATEMENT 
This press release contains statements, which may constitute
"forward-looking statements" within the meaning of the Securities Act
of 1933 and the Securities Exchange Act of 1934, as amended by the
Private Securities Litigation Reform Act of 1995. Those statements
include statements regarding the intent, belief or current
expectations of SOHM, Inc., and members of their management as well
as the assumptions on which such statements are based. Prospective
investors are cautioned that any such forward-looking statements are
not guarantees of future performance and involve risks and
uncertainties, and that actual results may differ materially from
those contemplated by such forward-looking statements. Important
factors currently known to management that could cause actual results
to differ materially from those in forward-statements include
fluctuation of operating results, the ability to compete successfully
and the ability to complete before-mentioned transactions. The
company undertakes no obligation to update or revise forward-looking
statements to reflect changed assumptions, the statements to reflect
changed assumptions, the occurrence of unanticipated events or
changes to future operating results. 
For More Information
Contact Investor Relations At
SOHM Inc
714-522-6700 
 
 
Press spacebar to pause and continue. Press esc to stop.